SpyBiotech Raises $32.5M in Series A Funding
Summary
The company intends to use the funds to advance the clinical development of its novel vaccine technology platform planning to begin a Phase I clinical study of its internal lead candidate, targeting human cytomegalovirus (HCMV), in early 2022. In September 2020, the company signed an exclusive global licensing agreement with the Serum Institute of India (SII) for the development of a novel virus-like particle (VLP) vaccine targeting COVID-19. Lutz has significant operational, governance and investment experience gained over the course of a 30 plus year career in biopharma in the US. He has served on the Boards of 16 biopharma companies and held several executive positions, including Managing Partner at SV Life Sciences, an international healthcare focused venture capital firm, based in San Francisco. SpyBiotech further strengthens its Board through the appointment of Andre Crawford-Brunt, General Partner, Braavos Investment Advisers.
Funding
Review available funding amount, funding date, investors, and linked company information related to SpyBiotech Raises $32.5M in Series A Funding in the interactive ISVWorld profile.